The enhancement of OXY’s anti-cancer effects on conventional chemotherapy was consistent with previous studies, which showed that OXY combined with doxorubicin promoted dose-dependent reductions in cell viability in breast and lung cancer cells [46,47]. The gene discussed is GCG; the disease is cancer.